Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

22.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anaptysbio Inc

< Previous 1 2 Next >
Anaptys Announces Participation in November and December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi 
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Participation in Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.